Yesterday, an advisory committee to the U.S. Food and Drug Administration met to discuss a serious problem: confusing names for prescription drugs. The committee’s decision, reportedly, is that more study is needed.
Yesterday, an advisory committee to the U.S. Food and Drug Administration met to discuss a serious problem: confusing names for prescription drugs. The committee’s decision, reportedly, is that more study is needed.
